Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials

Cancer

Volumn 119, Issue 2, 2013, Pages 285-292

  Bauer, Todd M ^a   El Rayes, Bassel F ^b   Li, Xiaobai ^c   Hammad, Nazik ^d   Philip, Philip A ^e   Shields, Anthony F ^e   Zalupski, Mark M ^f   Bekaii Saab, Tanios ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

carbohydrate antigen 19 9; gemcitabine; outcomes; pancreatic; predictive; prognostic

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CELECOXIB; CISPLATIN; DOCETAXEL; ETANERCEPT; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CA-19-9 ANTIGEN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84872053921     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27734     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ,. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996; 78 (3 suppl): 627-632.
3. Brambs HJ, Claussen CD,. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993; 25: 58-68.
4. Koprowski H, Herlyn M, Steplewski Z, Sears HF,. Specific antigen in serum of patients with colon carcinoma. Science. 1981; 212: 53-55.
5. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V,. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006; 70: 255-264.
6. von Rosen A, Linder S, Harmenberg U, Pegert S,. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas. 1993; 8: 160-165.
7. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM,. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987; 47: 5501-5503.
8. Castellanos E, Berlin J, Cardin DB,. Current treatment options for pancreatic carcinoma. Curr Oncol Rep. 2011; 13: 195-205.
9. Hammad N, Heilbrun LK, Philip PA, et al. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. Asia Pac J Clin Oncol. 2010; 6: 98-105.
10. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D,. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005; 93: 740-743.
11. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002; 32: 35-41.
12. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009; 115: 2630-2639.
13. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008; 9: 132-138.
14. Wasan HS, Springett GM, Chodkiewicz C, et al. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer. 2009; 101: 1162-1167.
15. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL,. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998; 77: 325-328.
16. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V,. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000; 82: 1013-1016.
17. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003; 26: 462-467.
18. Ziske C, Schlie C, Gorschlüter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003; 89: 1413-1417.
19. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA,. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005; 93: 195-199.
20. Martin LK, Li X, Kim SE, et al. A multi-center phase II study of the combination of bevacizumab, fixed dose rate gemcitabine, and infusional 5-fluorouracil in patients with advanced pancreas cancer. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; April 18-22, 2009; Denver, CO. Philadelphia, PA: AACR; 2009. Abstract 4500.
21. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001; 92: 569-577.
22. Hill ME, Li X, Kim S, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2011; 67: 511-517.
23. El-Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol. 2003; 21: 2920-2925.
24. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005; 23: 583-590.
25. Kosuri KV, Bekaii-Saab TS, Bender J, et al. Disrupting TNF signaling in pancreatic cancer: A phase I/II clinical study in patients with advanced disease [Abstract]. Proceedings of the 2005 ASCO Annual Meeting. J Clin Oncol. 2005; 23 (suppl): abstract 4103.
26. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
27. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA,. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008; 37: 269-274.
28. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29: 4548-4554.
29. Mamon HJ, Niedzwiecki D, Hollis D, et al. Cancer and Leukemia Group B. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011; 117: 2620-2628.
30. Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011; 67: 249-254.
31. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S,. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010; 44: 286-288.
32. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26: 942-947.
33. Swets JA, Pickett RM,. Evaluation of Diagnostic Systems: Methods From Signal Detection Theory. New York: Academic Press; 1982.
34. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 2212-2217.
35. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-3952.
36. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95: 587-592.
37. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27: 5513-5518.
38. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 28: 3605-3610.
39. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28: 3617-3622.